Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

A women with hand osteoarthritis rubs her hands together

Hand osteoarthritis affects more than two million people in the UK. There are few evidence-based interventions to treat the condition, other than pain relief and exercise, which are often inadequate. The NIHR-funded HOPE-e study is recruiting post-menopausal women to see whether painful osteoarthritis in joints of their hands can be treated with hormone replacement therapy (HRT).

The study is currently recruiting women aged 40 to 65 years old who are between one and 10 years after their menopause. Participants will take either a type of HRT tablet or a placebo (inactive tablet) for 24 weeks.

Like many research studies during the Coronavirus pandemic, the HOPE-e study paused recruitment on 16 March 2020, but were delighted to be able to restart the study from the end of August at various sites including the Nuffield Orthopaedic Centre, part of Oxford University Hospitals NHS Foundation Trust in Oxford.

The study team has made several modifications to the study to allow it to run in the new COVID-secure era. Four of the five study visits are now typically carried out remotely over the telephone with only the first screening visit requiring a face-to-face visit to the clinic.

Professor Fiona Watt, HOPE-e Chief Investigator, based at University of Oxford's Kennedy Institute of Rheumatology, says "With all bar one of the study visits now possible remotely, COVID has taught us how much we can do by phone and online. 

"Just like the NHS, research needs to be flexible and change to new models where we can, whilst making sure everyone stays safe. Ultimately, we hope this 'new look' may also prove popular with women who work, have busy lives or live further away who have painful hand osteoarthritis and want to take part in the study."

The study is recruiting participants until the end of December 2020.

More information on taking part can be found on the HOPE-e website.

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.